IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors

– Dr. Hambleton Brings More Than 25 Years of Industry and Academic Experience –

MOUNTAIN VIEW, Calif., Aug. 15, 2018 – IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Julie Hambleton, M.D., to its Board of Directors. Dr. Hambleton has more than 25 years of academic and industry experience, including 15 years as a leader in preclinical and clinical development at Bristol-Myers Squibb, Five Prime Therapeutics, Clovis Oncology and Genentech. Currently Senior Vice President, Chief Medical Officer and Head of Development at IDEAYA Biosciences, Dr. Hambleton has broad experience across all stages of drug development and was a leader in the successful development of Avastin® and Rubraca®.

“Julie has been at the forefront of some of the most significant advances in oncology/immuno-oncology and hematology, serving as a highly respected medical director and clinical development leader for early-stage companies as well as for some of the most recognized biotechnology and pharmaceutical companies involved in cancer research today,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Her tremendous wealth of experience leading preclinical and clinical operations and strategy, combined with her global regulatory and post-marketing development experience, will be a significant asset, providing IGM with a broad perspective as we advance our pipeline of IgM oncology antibodies into the clinic, and we look forward to her leadership and guidance as a member of our Board of Directors.”

“IGM Biosciences is pioneering an entirely new approach to treating cancer with the development of IgM antibodies that have the potential to significantly expand and advance our current oncology treatment options,” said Dr. Hambleton. “Preclinical observations with IGM’s proprietary IgM antibodies suggest that their novel approach to creating high-avidity IgM antibodies may allow for the successful treatment of a broad range of cancer patients for whom traditional IgG antibodies and other drugs have failed. I have had the privilege to work with some of the industry’s most groundbreaking research and development teams, and I am very excited to be joining IGM as a member of its Board as the company advances its technology toward the clinic.”

Dr. Hambleton currently serves as Senior Vice President, Chief Medical Officer and Head of Development for IDEAYA Biosciences, an oncology-focused biotechnology company. Prior to IDEAYA, Dr. Hambleton was Vice President and Head of U.S. Medical Affairs Research and Development at Bristol-Myers Squibb, where she was responsible for U.S. medical affairs for immuno-oncology/oncology, immunoscience, cardiovascular and virology products, managing a team of 350 employees. At Five Prime Therapeutics, she led preclinical and clinical development, most recently as Executive Vice President and Chief Medical Officer, and she was a member of the IPO and follow-on financing teams. She was also Vice President of Clinical Development at Clovis Oncology. Dr. Hambleton began her career in the biotechnology industry in 2003 at Genentech as Medical Director for the Avastin program. While at Genentech, Dr. Hambleton served in positions of increasing responsibility, overseeing exploratory clinical development for the company’s antiangiogenic pipeline, expansion of Avastin’s clinical program to support approval of Avastin for renal-cell carcinoma and glioblastoma, and she was most recently Group Medical Director of Global Clinical Development, BioOncology, leading the global, cross-functional team responsible for successful clinical trial execution and multiple marketing authorization applications for the Avastin Breast/Ovarian-GYN program.

Dr. Hambleton completed her medical and oncology-hematology training at the University of California, San Francisco, where she then served on faculty until 2003. She received a B.S. from Duke University and an M.D. from Case Western Reserve University School of Medicine, and she is an author or co-author of more than 50 scientific publications.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been dedicated since 2010 to creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases. IGM Biosciences is focused on developing and utilizing IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:
Argot Partners
David Pitts
212-600-1902
igmbiosciences@argotpartners.com

IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors

– Dr. Daniel Chen, Former Global Head of Cancer Immunotherapy Development at Genentech/Roche and Noted Immuno-Oncology Expert, to Lead Company’s Emerging Clinical Development Initiatives –

– Dr. William Strohl, Preeminent Leader in Antibody Research and Development, Brings Wealth of Antibody Engineering Experience –

MOUNTAIN VIEW, Calif., Aug. 1, 2018 – IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointments of Daniel S. Chen, M.D., Ph.D., to the newly created position of Chief Medical Officer and William Strohl, Ph.D., to its Board of Directors.

Dr. Chen will be responsible for global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. He joins IGM with more than 20 years of experience in cancer immunotherapy research and development, most recently as Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche.

Dr. Strohl is one of the world’s preeminent leaders in novel antibody engineering. He was formerly Vice President and Head, Janssen BioTherapeutics, Janssen R&D, Johnson & Johnson (J&J), where he ran biologics discovery, early development and technology development.

“Dan and Bill are both pioneers in novel antibody development, and they each bring a wealth of experience and knowledge that will help direct and accelerate the progress of our groundbreaking IgM antibody platform and help guide our lead candidates into and through the clinic,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Dan is widely regarded as a global leader in immuno-oncology, and he oversaw some of the most important R&D in oncology over the last decade while at Genentech/Roche, making his decision to join IGM a strong endorsement of the potential of our technology and our emerging pipeline. Bill is widely regarded as a global thought leader in antibody engineering and novel antibody development, and we look forward to his contributions as a member of our Board of Directors.”

Dr. Chen commented: “IGM’s proprietary scientific and technological approach represents an exciting new frontier for the development of antibody treatments for cancer and other serious diseases. The company’s IgM antibodies have unique advantages over traditional IgG antibodies in that they offer stronger binding to more difficult and rare targets, as well as superior agonist potency. Preclinical research and models suggest the potential for IgM antibodies to offer dramatically superior efficacy to IgG antibodies in certain clinical indications. As a clinician who has been immersed in the immuno-oncology space through what could be described as its most dramatic period of growth, I see tremendous potential in the translation of IGM technology to the clinic.”

“Engineered IgG antibodies remain the bedrock of therapeutic antibody drugs, yet the structural and functional limitations of IgG antibodies are well established,” said Dr. Strohl. “The possibility that IgM antibody technology may address some of these limitations is extremely exciting, and IgM antibodies have tremendous potential to serve unmet medical needs. IGM Biosciences is the clear global leader in the development of IgM antibodies, and I look forward to working with the Board and management team in advancing this groundbreaking new technology.”

Dr. Chen began his tenure with Genentech/Roche in 2006 and was instrumental in building the company’s cancer immunotherapy segment, most recently serving as Vice President, Global Head of Cancer Immunotherapy Development and Cancer Immunotherapy Franchise Head. While with Genentech/Roche, Dr. Chen focused on the clinical development of anti-angiogenic and immune-modulatory targeted therapies in both early- and late-stage development, as well as the diagnostic tools to aid in their development, and he led development of the anti-PD-L1 antibody drug Tecentriq® from preclinical through post-marketing.

Prior to joining Genentech/Roche, Dr. Chen ran the metastatic melanoma clinic at the Stanford Cancer Center where he studied human anti-cancer immune responses to cancer vaccination and cytokine administration and co-invented and developed an MHC cellular microarray to detect and functionally characterize antigen-specific T-cell states. After joining Genentech, Dr. Chen continued as Adjunct Clinical Faculty and was a treating physician for patients with melanoma at Stanford until 2016. He currently serves as co-chair of the Cancer Research Institute’s Cancer Immunotherapy Consortium and was recently elected to the board of the Society for Immunotherapy of Cancer (SITC). Dr. Chen is a noted immuno-oncology expert and speaker, and he delivered the keynote presentation at the AACR NCI EORTC Annual Conference in 2014 and presented at the U.S. Congressional Briefing on Immuno-Oncology in 2017. He is a reviewer for the scientific journals Nature, Immunity and Clinical Cancer Research, and he has co-authored a number of prominent scientific papers in the field of cancer immunotherapy, including the often-referenced Chen and Mellman manuscripts, “Elements of cancer immunity and the cancer-immune set point” and “Oncology meets immunology: the cancer-immunity cycle.” Dr. Chen received a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in microbiology and immunology and an M.D. from the University of Southern California.

Prior to retiring from J&J in August 2016, Dr. Strohl was Vice President and Head, Janssen BioTherapeutics, Janssen R&D, J&J. Previously, Dr. Strohl was Head of Biologics Research, the discovery arm of Janssen BioTherapeutics.  During his time at J&J, Dr. Strohl was responsible for advancing more than 30 novel antibodies into development.

Before joining J&J, Dr. Strohl was with Merck and Co. from 1997 until 2008. At various points during his tenure at Merck, Dr. Strohl led the company’s biologic drug discovery efforts, was involved in multiple biotechnology company acquisitions and licenses to improve discovery capabilities, established its Microbial Vaccines segment and led its Natural Products Biology group. Prior to his work in industry, Dr. Strohl was a Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University. Dr. Strohl has authored or co-authored more than 140 scientific publications, including “Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry,” which was published in October 2012. Dr. Strohl is also an inventor or co-inventor on 17 issued patents. Dr. Strohl earned a Ph.D. in microbiology and biochemistry from Louisiana State University.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been dedicated since 2010 to creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases. IGM Biosciences is focused on developing and utilizing IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:
Argot Partners
David Pitts
212-600-1902
igmbiosciences@argotpartners.com

Senior Research Associate, Upstream Process Sciences

IGM Biosciences is a privately held, biotechnology company focused on the discovery and development of innovative therapeutic antibodies for the treatment of cancer, autoimmune disorders and infectious diseases. Since 2011, we have pioneered a new field of antibody development by creating novel IgM and IgA antibodies. Our proprietary platform of high avidity, natural and engineered human antibodies utilizes novel mechanisms of action that specifically target cell types involved in disease pathways. We are building a strong pipeline of biologics for oncology, infectious disease and immunology disease drug candidates. We are also in partnership with other biopharmaceutical companies as the preferred CMO for production of IgM and IgA antibodies for specific clinical applications.

We are hiring a Senior Research Associate in our Upstream Process Sciences group. This position supports the development of novel antibody products by helping to create upstream processes producing these therapeutic antibodies. The Senior Research Associate is expected to maintain and expand cells, support the upstream PD lab, and to set up and execute antibody production runs at scale up to 25 liters or larger if needed.

Essential Duties and Responsibilities

  • Maintains and passages CHO expression cell lines.
  • Transfects plasmids into expression cells for transient production.
  • Selects and expands expression cell lines for both stable and transient production.
  • Maintains upstream development lab.
  • Determines expression titer by ELISA and other techniques.
  • Documents results in laboratory notebooks.
  • Searches the literature to identify alternative methodologies and solve scientific problems, establish and qualify assays.
  • Prepares technical reports, summaries, and detailed protocols.
  • Learns new techniques as the job requires.
  • Shares data with management and team members.

Job Requirements

  • Education:  BS/BA or higher degree in a biology-related discipline.
  • Experience:  3-5 years of experience working with mammalian cell culture and bioreactor/wave systems.
  • Knowledge, Skills and Abilities
    • Proficiency using Microsoft Office
    • Aseptic technique
    • Ability to multitask

Special Working Conditions

  • This job entails working under BSL-2 conditions.

Process Analytical Scientist

IGM Biosciences is a privately held, biotechnology company focused on the discovery and development of innovative therapeutic antibodies for the treatment of cancer, autoimmune disorders and infectious diseases.  Since 2011, we have pioneered a new field of antibody development by creating novel IgM and IgA antibodies.  Our proprietary platform of high avidity, natural and engineered human antibodies utilizes novel mechanisms of action that specifically target cell types involved in disease pathways. We are building a strong pipeline of biologics for oncology, infectious disease and immunology disease drug candidates.

We are seeking a collaborative and driven Analytical Scientist to work alongside our Process Sciences Group.  This position will report to the VP, Manufacturing and Process Sciences.  The position is responsible for analytical method development activities associated with the development of manufacturing processes for sterile injectable drug products including monitoring of upstream and downstream process steps, testing and characterization of drug substance and drug product.  The position also participates in formulation development and supports research and development in clinical candidate selection.

Essential Duties and Responsibilities:

  • Responsible for analytical test methods development to support in-process, drug substance and drug product testing
  • ‪Provides analytical characterization for research and development for selection of new pre-clinical candidates
  • Performs development stability studies and studies in response to FDA information requests
  • ‪Correctly executes development activities as defined by senior scientific staff or management. Initiates and designs studies, as appropriate
  • Applies basic scientific principles, technology and regulatory knowledge with minimal guidance
  • Demonstrates the ability to interpret outcome of experiments and to propose appropriate follow-up experiments
  • Trains personnel on analytical methods to enable them to perform independently
  • Communicates own work effectively orally and in writing
  • Contributes and/or prepares protocols, testing procedures, and technical reports.
  • Performs literature searches and extracts relevant information from published information
  • Reports and treats data with a high level of integrity and ethics
  • Thoroughly and accurately documents experimental activities in laboratory notebooks.

 Desired Education, Skills and Experience:

  • BS/BA or higher degree in a scientific discipline
  • 3-10 years of relevant experience
  • Experience in hands on analytical methods development in a pharmaceutical environment working on protein therapeutics preferably monoclonal antibodies
  • ‪Able to demonstrate proficiency in HPLC and Electrophoresis instrumentation and software is required
  • Experience working with samples from recombinant manufacturing processes preferred
  • Knowledge of basic computer programs routinely used in a lab such as MS Word, Powerpoint, Excel, GraphPad, etc.
  • Ability to quickly learn and master new instrument software and programs.
  • Excellent organization, interpersonal, and communication skills.
  • Being a team player and respectful of others is a must.
  • Experience in maintaining thorough lab records, and adhering to health and safety regulations
  • Ability to thrive in a fast-paced, small start-up environment

Special Working Conditions:

Travel approximately 10% of the time

If you are interested in joining an exciting antibody creation and development company, please submit your cover letter and resume to jobs@igmbio.com.

 

The job description outlined above reflects general details as necessary to describe the primary functions of this job, the level of knowledge and skill typically required, but should not be construed as an all-inclusive listing of work requirements. Individuals may be asked to perform duties other than those mentioned above in order to cover absences or relief in the appropriate department to equalize peak work periods or otherwise balance the workload.

All qualified applicants will receive consideration for employment without regard to race, sex, color, religion, national origin, protected veteran status, or on the basis of disability, gender identity, and sexual orientation.